Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Targeted Therapy for Metastatic Non–small Cell Lung Cancer

August 12th 2021

Mark A. Socinski, MD shares a brief overview of the biomarkers and FDA-approved targeted therapies for non–small cell lung cancers.

SCLC: Rechallenging With Chemotherapy + I/O

August 12th 2021

Anne Chiang, MD, PhD, renowned expert in thoracic oncology, guides a discussion on whether to rechallenge with chemotherapy + I/O after progression of small cell lung cancer.

Clinical Endpoints and Neoadjuvant Therapy for Resectable NSCLC

August 11th 2021

The impact of endpoints used in clinical trials of neoadjuvant therapy for resectable non–small cell lung cancer as they relate to newer drug approvals and real-world practice.

Neoadjuvant Immunotherapy for Resectable NSCLC

August 11th 2021

Martin Dietrich, MD, PhD, describes his interpretations of the KEYNOTE-799 study of pembrolizumab plus chemoradiation therapy for unresectable stage III non–small cell lung cancer.

Native American Ancestry Correlates With EGFR, KRAS Mutations in Lung Cancer

August 6th 2021

An association has been found in Latin American patients with lung adenocarcinoma between Native American ancestry and somatic landscape, including EGFR, KRAS, and STK11 mutations, as well as tumor mutational burden.

Cemiplimab/Chemo Combo Significantly Improves OS Over Chemo Alone in Frontline Advanced NSCLC

August 5th 2021

The combination of cemiplimab-rwlc plus platinum-doublet chemotherapy was found to significantly improve overall survival over chemotherapy alone in the frontline treatment of patients with advanced non–small cell lung cancer, meeting the primary end point of the phase 3 EMPOWER-Lung 3 trial.

SCLC: Second-Line Options and Supportive Care

August 5th 2021

Key opinion leaders in thoracic oncology provide insights into second-line treatment for patients with relapsed/refractory small cell lung cancer and comment on the role of trilaciclib in managing cisplatin-associated neutropenia.

Single Agent I/O Therapy for Relapsed/Refractory

August 5th 2021

Lung cancer expert Anne Chiang, MD, PhD, considers the recent withdrawal of FDA-accelerated approval for nivolumab and pembrolizumab for patients with relapsed extensive-stage small cell lung cancer.

Unmet Needs in Non–Small Cell Lung Cancer

August 5th 2021

Unmet needs including strategies to manage brain metastases in non–small cell lung cancer patients are presented.

New Therapies in Non–Small Cell Lung Cancer

August 5th 2021

Alexander Spira, MD, PhD, FACP, highlights emerging targeted agents to treat non–small cell lung cancer with actionable mutations.

Recent FDA-Approvals: MET Exon 14 Mutations in NSCLC

August 5th 2021

An expert in non–small cell lung cancer (NSCLC) provides an overview of recent data presented at the American Society of Clinical Oncology 2021 annual meeting to treat MET exon 14 mutations.

Recent FDA-Approvals: HER2-Mutated NSCLC

August 5th 2021

Edward Kim, MD, MBA, summarizes recent data for HER2-mutated in non–small cell lung cancer (NSCLC) presented at the American Society of Clinical Oncology 2021 annual meeting.

Dr. Malhotra on the Rationale to Evaluate Racial Disparities in Lung Cancer Survivors

August 5th 2021

Jyoti Malhotra, MD, MPH, discusses the rationale to evaluate racial disparities in lung cancer survivors.

Plinabulin Plus Docetaxel Significantly Improves OS in EGFR Wild-Type NSCLC

August 4th 2021

The combination of plinabulin plus docetaxel resulted in a statistically significant improvement in overall survival vs docetaxel alone when used in the second- or third-line treatment of patients with EGFR wild-type, non–small cell lung cancer and measurable lung lesions.

CRT and I-O for Unresectable Stage III NSCLC

August 4th 2021

Martin Dietrich, MD, PhD, describes his interpretations of the KEYNOTE-799 study of pembrolizumab plus chemoradiation therapy for unresectable stage III non–small cell lung cancer.

Appropriateness for Durvalumab in Unresectable Stage III NSCLC

August 4th 2021

Variables that influence patient selection for durvalumab consolidation after CRT as part of treatment for unresectable stage III non–small cell lung cancer.

Dr. Ozguroglu on the Individualization of Treatment in NSCLC

August 3rd 2021

Mustafa Özguröğlu, MD, discusses the individualization of treatment in non-small cell lung cancer.

Dr. Puri on Clinically Relevant Biomarkers in SCLC

August 3rd 2021

Sonam Puri, MD, discusses recent research on clinically relevant biomarkers in small cell lung cancer.

KRAS Inhibitors, Immunotherapy, and ADCs Carve Out Newfound Applications in NSCLC

August 3rd 2021

The 2021 ASCO Annual Meeting was chock full of practice-changing, practice-affirming, and exciting preliminary research in non–small cell lung cancer, said Melissa Johnson, MD.

FDA Grants Priority Review to Adjuvant Atezolizumab for PD-L1+ Early-Stage NSCLC

August 3rd 2021

The FDA has granted priority review to a supplemental biologics license application for atezolizumab as an adjuvant treatment after surgery and platinum-based chemotherapy in patients with non–small cell lung cancer whose tumors have a PD-L1 expression of 1% or higher per an FDA-approved test.